Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
21st Century Neurology
Phoenix, Arizona, United States
Medical Center for Clinical Research
San Diego, California, United States
Sensible Healthcare
Ocoee, Florida, United States
University of South Florida
Tampa, Florida, United States
Renstar Medical Research
Wesley Chapel, Florida, United States
Boston Clinical Trials
Boston, Massachusetts, United States
Michigan Head, Pain and Neurological Institute
Ann Arbor, Michigan, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
Healthy Perspectives Innovative Mental Health Services, PL
Nashua, New Hampshire, United States
Bio Behavioral Health
Toms River, New Jersey, United States
Start Date
July 31, 2018
Primary Completion Date
June 19, 2019
Completion Date
September 19, 2019
Last Updated
July 8, 2020
463
ACTUAL participants
Galcanezumab
DRUG
Placebo
DRUG
Lead Sponsor
Eli Lilly and Company
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions